Background: Tachycardia-induced remodeling likely plays an important role in atrial fibrillation (AF) maintenance and recurrence 21 after cardioversion, and Ca overload may be an important mediator. This study was designed to evaluate the relative efficacies of 21 selective T-type (mibefradil) and L-type (diltiazem) Ca -channel blockers in preventing tachycardia-induced atrial remodeling. Methods: Dogs were given daily doses of mibefradil (100 mg), diltiazem (240 mg) or placebo in a blinded fashion, beginning 4 days before and continuing through a 7-day period of atrial pacing at 400 bpm. An electrophysiological study was then performed to assess changes in refractoriness, refractoriness heterogeneity and AF duration. Results: Mean duration of burst-pacing induced AF was similar in placebo (5676203 s) and diltiazem-treated (9636280 s, P5NS) animals, but was much less in mibefradil-treated dogs (3.660.9 s, P,0.002) and non-paced controls (6.662.7 s). In contrast to mibefradil, diltiazem did not alter tachycardia-induced refractoriness abbreviation or heterogeneity. To exclude inadequate dosing as an explanation for diltiazem's inefficacy, we studied an additional group of dogs treated with 720 mg / day of diltiazem, and again noted no protective effect. Acute intravenous administration of diltiazem to control dogs failed to alter atrial refractoriness or AF duration, excluding a masking of remodeling suppression by offsetting 21 profibrillatory effects of the drug. Conclusions: Whereas the selective T-type Ca -channel blocker mibefradil protects against atrial remodeling caused by 7-day atrial tachycardia, the selective L-type blocker diltiazem is without effect. These findings are potentially important for understanding the mechanisms and prevention of clinically-relevant atrial-tachycardia-induced remodeling.
Introduction
available therapy, there has been interest in developing drug therapy directed against novel therapeutic targets, Atrial fibrillation (AF) is an extremely common arrhythincluding the substrate for arrhythmia [4] . One potentially mia, with an incidence that is increasing with the aging of interesting target is the remodeling process leading to the population [1, 2] . The treatment of AF remains subopti-AF-promoting electrophysiological changes that result mal, with antiarrhythmic drugs to maintain sinus rhythm from atrial tachycardias, particularly AF [5] . Sustained being plagued by a significant risk of ventricular proatrial tachycardia causes a variety of electrophysiological arrhythmia [3] . Because of the limitations of presently alterations, including atrial effective refractory period (ERP) abbreviation [6-10] and increases in refractoriness heterogeneity [10, 11] , that promote AF inducibility and maintenance. 21 There is evidence for Ca -overload as an initiating 2. Methods signal for tachycardia-induced remodeling [5, 9, 12] . Ex- 21 perimental and clinical studies suggest that Ca -channel 2.1. Instrumentation for rapid pacing blockers may prevent the effects of atrial tachycardia on atrial ERP [9, [13] [14] [15] and mechanical properties [16, 17] .
Adult mongrel dogs (27.160.6 kg, n537) were anesThe clearest evidence comes from studies of short-term thetized with pentobarbital (30 mg / kg i.v., additional AF, the effects of which on atrial electrophysiology, doses of 4 mg / kg as needed). In an initial procedure, tined arrhythmia promotion and mechanical dysfunction are unipolar pacing leads were inserted in the right atrial (RA) prevented [13, 14, 16, 17] . Studies of longer-term verapamil appendage (RAA) and in the right ventricular (RV) apex administration have provided varying results [15, 18] .
under fluoroscopic guidance and connected to pacemakers A retrospective analysis of clinical data showed that implanted subcutaneously in the neck. AV block was 21 patients treated with either b-blockers or Ca antagonists, created with radiofrequency energy (30-40 W for 20-30 when considered as a single group, appeared to have s). The average number of radiofrequency applications was reduced AF recurrence after cardioversion (differences 1.960.4 . No dogs recovered AV-nodal conduction during 21 were not significant for either the b-blocker or Ca the study. The ventricular demand pacemaker was proantagonist group alone) [19] . These findings have led to grammed to capture the ventricles at 80 bpm, and the atrial speculation that I blockers may prevent tachycardiapacemaker was activated to pace the atria with twiceCa.L induced remodeling and constitute useful adjunctive threshold pulses at 400 bpm. Atrial and ventricular pacing therapy for AF patients. This suggestion contrasts with a were applied continuously during the 7-day rapid atrial recent report of apparent inefficacy of verapamil in prepacing period (days 5-12, Fig. 1 ) prior to electrophysioventing remodeling caused by long-term atrial tachycardia logical study. Animal handling procedures were approved [18] .
by the Montreal Heart Institute Animal Ethics Committee 21 In a previous study, we showed that the T-type Caand followed the guidelines of the Canadian Council for current (I ) blocker mibefradil reduces electrophysioAnimal Care (CCAC).
Ca.T logical remodeling caused by 7 days of atrial tachycardia in dogs [20] . Although most studies of mibefradil show it 2.2. Experimental protocol 21 to be much more potent as a T-type Ca -channel blocker than as an L-type blocker [21] [22] [23] , the drug nevertheless In rapidly-paced dogs, one 100 mg tablet / day of mibefcan clearly inhibit L-type channels considerably [24] . The radil (n512 dogs), one 240 mg tablet / day of Cardizempossibility cannot therefore be excluded that mibefradil's CD, a slow-release diltiazem preparation (n510 dogs), or I -blocking properties are responsible for its ability to matching placebo (n515 dogs) was given in a blinded
Ca.L prevent atrial tachycardia-induced electrical remodeling. fashion, beginning 4 days before pacemaker implantation The recently-reported inefficacy of verapamil [18] could and continuing until 24 h before the day of electrohave been due to collateral properties, such as verapamil's physiological study (Fig. 1) . Although we have reported on 1 strong K -channel blocking action [25] , to inadequate oral the effects of mibefradil in this model in a previous doses (plasma concentrations were not measured) or to publication [20] , we felt that it was essential to study the contaminating effects of acute intravenous verapamil addrug in another series of dogs to compare directly and in a ministration, which was given to all dogs in the chronic blinded fashion the effects of mibefradil with those of verapamil group at the time of electrophysiological study diltiazem to minimize the possibility of erroneous concluand could have had acute AF-promoting effects. In order to sions due to time-related and inter-animal variation or to address the issue of the potential role of T-vs. L-type bias. Blood samples were obtained prior to anesthesia on 21 Ca -channel blocking action in preventing atrial remodelstudy days for subsequent measurement of plasma diling, we compared the effects of mibefradil with those of tiazem concentration by high-pressure liquid chromatogthe highly-selective I -blocker diltiazem on atrial reraphy. A group of size-matched dogs (n512) without Ca.L modeling caused by 7 days of rapid atrial pacing in the pacemaker implantation was used as a control group dog. We chose to study diltiazem because, in contrast to ( after 7 days, with only small additional decreases noted performed. The study preparation and instrumentation after 42 days of rapid pacing [26] . Preliminary results of were as previously described [10, 11] . A mapping system the present study have been presented in abstract form was connected to five arrays covering the atrial epicardial [27] .
surfaces with 240 bipolar electrodes as in our previous Fig. 1 . Schematic outline of study design. PM5pacemaker. Mibefradil, placebo or diltiazem were received in coded bottles and administered as a single morning dose, beginning 4 days before the onset of rapid-pacing and continuing during the 7-day rapid-pacing period. The last dose was administered 24 h before electrophysiological study.
work [20] . Signals were filtered (10-900 Hz), digitized inferior free wall. ERP was determined in the same regions (12-bit resolution, 2-kHz sampling), and transmitted into a as for CV measurements, allowing for the calculation of Silicon Graphics computer. Activation data were analyzed local wavelength as the product of mean local CV and off-line with computer-determined peak-amplitude criteria, ERP. A 15-stimulus basic train at a basic cycle length and data for each electrode were reviewed manually.
(BCL, 2-ms, twice-threshold current pulses) of 300 ms was followed by a premature extrastimulus (2-ms, twice-thres-2.3. Electrophysiological study hold current) at a progressively-increasing coupling interval and a 2-s pause to observe the response between trains. Atrial effective refractory period (ERP) and conduction
The coupling interval was increased by 10-ms increments velocity (CV) were measured during stimulation at sites in to obtain an initial ERP estimate. The measurement was various atrial regions as in previous work [11] . Activation then repeated with 5-ms increments and the resulting value maps for CV measurement were obtained after 60 s at a taken as the ERP if it was within 10 ms of the first basic cycle length (BCL) of 300 ms. CV was measured estimate. In the case of a $10-ms difference between with the use of two parallel sets of electrodes (four bipolar measurements, a third measurement with 5-ms steps was electrodes / set) during local pacing in each of five regions:
obtained and the mean of all three ERP values was used. Bachmann's bundle (BB), the left atrial (LA) appendage AF vulnerability was determined from the response to (LAA), the RAA, the RA superior free wall and the RA single S extrastimuli (S s) at coupling intervals of 5 and 2 2 10 ms longer than the ERP at each site used for ERP Wallis rank sum test (when data could not be assumed to determination. The vulnerability at each site was defined be normally-distributed) was used for multiple-group by the ability of single S s to induce in a reproducible comparisons, followed by a range test. A chi-square test 2 fashion AF that lasted .1 s. Overall vulnerability in each was used for contingency comparisons. Averages are given dog was defined as the percentage of sites at which AF as mean6S.E.M., and a two-tailed P,0.05 was considered was inducible. Because in some dogs AF was not inducible statistically-significant. by single extrastimuli, AF was also induced by stimulating the RAA with 10-Hz, 2-ms stimuli at four times threshold current for 2-10 s. To calculate mean AF duration, AF 3. Results was induced with burst pacing ten times for AF duration ,10 min and twice for AF duration .10 min. AF that 3.1. Overall electrophysiological changes lasted .20 min was terminated by direct current electrical cardioversion, and 20 min allowed before repeating AF Control, placebo, mibefradil and diltiazem dogs showed induction. no significant differences in size, number of sites for ERP determination, and atrial diastolic threshold (Table 1 ).
Data analysis
Mibefradil-treated dogs had a slower sinus rate compared to placebo, control and diltiazem dogs, consistent with the 21 The CV was determined in each region as previously role of T-type Ca channels in sinus-node automaticity described [11] and the overall CV for each dog calculated [21] . from the average of the five regional CV values. Overall wavelength was calculated as the mean of all ERP values 3.2. Effects on AF vulnerability and maintenance in each dog times the mean CV (not significantly different from the value obtained by multiplying ERP in each region Placebo-treated dogs subjected to 7-day rapid atrial by local CV and averaging the values). The coefficient of pacing had significantly-increased AF duration ( Fig. 2A ) ERP variance, calculated as (S.D. / mean)3100%, was used and vulnerability to AF induction (Fig. 2B) . AF duration as an index of ERP heterogeneity. The number of sites for of mibefradil-treated dogs (6.662.7 s) was reduced com-ERP determination in each region was equivalent across pared to placebo-treated dogs (5676203 s, P,0.002) and dogs and between groups. similar to non-paced control dogs (3.660.9 s, P5NS). In Statistical comparisons between two groups only were contrast, the AF duration of diltiazem-treated rapidlyperformed by Student's t-test or the Mann-Whitney rank paced dogs (9636280 s) was not significantly different sum test (for non-normally distributed data). Analysis of from placebo-treated rapidly-paced dogs and substantially variance (ANOVA, for parametric data) or a Kruskalgreater than non-paced controls (P,0.002). Changes in vulnerability to AF induction by single atrial premature average value in non-paced control dogs (11463 ms). In complexes were qualitatively similar to those in AF diltiazem-treated rapidly-paced dogs, ERP averaged 7464 duration. In placebo-treated dogs, rapid pacing led to a ms, similar to placebo-treated animals (7963 ms), with highly-significant increase in vulnerability, with AF inboth significantly reduced from control non-paced dogs duced by single extrastimuli at over 40% of sites per dog, (Fig. 3A) . Wavelength changes (Fig. 3C) reflected ERP compared to about 2% in non-paced controls (P,0.002, alterations, with mibefradil showing significant protection Fig. 2B ). Mibefradil greatly decreased vulnerability (AF against tachycardia-induced abbreviation and diltiazem no induced at fewer than 10% of sites, P,0.002 vs. placebo).
effect. In contrast to placebo-treated rapid-pacing dogs, Diltiazem administration was no better than placebo in mibefradil-treated dogs had a coefficient of variation in reducing AF vulnerability in rapidly-paced dogs, with AF ERP (17.061.2%) which was not significantly different inducible at nearly 60% of sites (P5NS vs. placebo, from the value in control dogs (14.160.8%). Diltiazem-P,0.002 vs. mibefradil).
treated rapidly-paced dogs had similar ERP heterogeneity (28.362.0%) to placebo animals (26.761.9%), with both 3.
Changes in electrophysiological properties
values significantly greater than in control (non-paced) and mibefradil-treated rapidly-paced dogs. Placebo-treated dogs subjected to 7 days of rapid-pacing had significantly reduced ERP (Fig. 3A) and unchanged 3.4. Regional changes in electrophysiological properties CV (Fig. 3B) . Wavelength changes paralleled those in ERP (Fig. 3C) . In addition to decreasing the absolute ERP Regional ERP differences under control conditions in value, rapid pacing also increased ERP heterogeneity (Fig. dogs are related to discrete ionic current distributions [28] , 3D). Mibefradil prevented the ERP-abbreviating effect of and increased ERP heterogeneity is important in tachrapid pacing, with the mean ERP in mibefradil-treated ycardia-induced remodeling [11] . Fig. 4 shows an analysis dogs (10365 ms) not significantly different from the of changes produced by each intervention in ERP values for each of four regions for which sufficient data were ERP (P5NS for each), consistent with diltiazem's lack of available. The results indicate that for each region studied, effect on mean ERP and AF duration. rapid pacing significantly decreased ERP values in placebo
The lowest diltiazem concentration 24 h after the last and diltiazem-treated dogs, but had much less (and statistidose of diltiazem averaged 2867 ng / ml, just below the cally non-significant) effect in mibefradil-treated animals.
therapeutic concentration of 40 ng / ml [29] . We therefore considered the possibility that diltiazem's inefficacy was due to insufficient plasma concentrations and studied an 3.5. Diltiazem plasma concentrations and effects of additional group of four dogs treated with 3-fold larger high-dose diltiazem doses, 720 mg / day (on a per-weight basis, equivalent to about 1680 mg / day, or five times the maximum clinical In our previous study, we showed that plasma mibefradil dose, in man). The same protocol as shown in Fig. 1 was concentrations were significantly related to AF duration used, except that the dose of diltiazem consisted of four and ERP in individual rapidly-paced dogs, consistent with 180-mg tablets each morning. This dose significantly concentration-dependent protection [20] . The effective reduced arterial pressure, from 12268 / 6665 mmHg in trough mibefradil concentrations in that study were in the placebo dogs to 9964/4463 mmHg in diltiazem-treated range of 100-400 ng / ml (0.2-0.7 mM). We were unable to dogs (P50.01). The sinus cycle length was also sigobtain mibefradil plasma concentration measurements for nificantly prolonged by high-dose diltiazem, from 396628 the dogs in the present study. However, we did measure to 605638 ms (P,0.05), indicating significant pharmacoplasma diltiazem concentrations and evaluated the relationlogical effects. After 7 days of rapid pacing, ERP in these ship with AF duration or atrial ERP. The correlation dogs (BCL 300 ms) was 81610 ms, not significantly coefficients were 20.42 (for AF duration) and 20.12 for different from placebo-treated dogs subjected to atrial tachycardia. Similarly, AF duration averaged 13426428 s the present study, we compared directly the effects of (vs. 5676203 s for placebo-treated rapidly-paced dogs), mibefradil with those of the I blocker diltiazem, finding with placebo or low-dose diltiazem. Thus, high-dose tachycardia-induced remodeling may be due to the duradiltiazem had no greater anti-remodeling effect than lowtion of atrial tachycardia. Most previous studies involved dose and the lack of diltiazem effect cannot be attributed to atrial tachycardia of ,24-h duration. The mechanisms of inadequate dosing.
short-term atrial-tachycardia remodeling are likely to be quite different from those of longer-term remodeling, the 3.6. Effects of acute diltiazem administration former being primarily functional and the latter related to altered gene-expression [5] . Thus, the role of I may
The acute administration of Ca antagonists has been well be different in mediating the effects of shorter-term reported to promote AF maintenance [30] . We considered vs. longer-term tachycardia. In agreement with this idea, the possibility that the lack of benefit from diltiazem may the effects of verapamil on AF promotion caused by atrial have been due to an acute pro-fibrillatory effect of the tachycardia lasting 24 h or greater [15, 18] are very drug, i.e. that remodeling might have been prevented, but different from its clear efficacy against AF promotion after that residual drug present in the blood may have itself 10-20 min of AF [12, 13] . decreased ERP and promoted AF, offsetting the effects mediated by inhibition of remodeling. To evaluate this 4.2. Novel findings and potential significance possibility, we infused diltiazem intravenously to four additional non-paced dogs at loading and maintenance This is the first study of which we are aware to compare doses previously shown to produce stable plasma diltiazem simultaneously the effects of a selective I blocker and a concentrations [31] . Acute administration of diltiazem did in long-term atrial tachycardia-induced action potential duration and refractory period changes [26] . Tachycardia-4. Discussion related ionic alterations are caused by decreased con- 21 centrations of mRNA encoding ion channel a-subunits We have shown that the Ca -channel blockers dil- [32] . The nature of the signal transduction system leading tiazem and mibefradil, with different selectivities for T-vs.
to ion-channel mRNA changes is unknown, but our L-type channels, have markedly different effects on elecfindings point to a potentially-important role of I . The trophysiological remodeling caused by 7-day atrial tachy- inhibition alone is insufficient to prevent tachycardia-L-type Ca channel blockade has been shown to inhibit Ca.L induced remodeling; however, they do not exclude the atrial remodeling caused by short-term (10-20 min) atrial possibility that inhibition of both I and I is needed, tachycardia [13, 14, 16, 17] . ERP changes induced by 7-24
Ca.L Ca. T 21 h of atrial tachycardia are attenuated by verapamil since mibefradil can affect both Ca -currents [21] [22] [23] [24] . It
21
[8, 15, 18] . Verapamil appears to have no effect on ERP or may be that the prevention of Ca overload during long-AF vulnerability changes induced by longer-term atrial term tachycardia (.24 h) requires the inhibition of both 21 tachycardia [18] , although in the latter study plasma drug Ca entry pathways. Alternatively, I may have Ca.T concentrations were not measured to ensure that adequate privileged access to systems regulating DNA transcription. blood levels were achieved by oral dosing. We previously Clinically, the notion of preventing atrial tachycardiashowed that mibefradil attenuates tachycardia-induced induced remodeling is an attractive new approach to ERP, AF duration and AF vulnerability changes [20] . In improving the management of AF [5, 19] . Tielemans et al. [19] analyzed retrospectively the rate of reversion to AF that I inhibition is the mechanism of protection. Other constitute an 'intracellular Ca -lowering drug' group. Our have been a more rapid ventricular rate in control than findings, particularly in combination with the similar drug (especially diltiazem) treated dogs. This could have observations on verapamil of Lee et al. [18] , raise quesresulted in drug effects on atrial remodeling due to tions about the ability of I blockers to prevent atrial differences in ventricular function rather than atrial reCa.L tachycardia-induced electrophysiological remodeling. A modeling per se. The potential disadvantages of this recent study [36] showed early recurrence (within 24 h) approach include atrial consequences of loss of AV following electrical cardioversion of AF in two of 44 synchrony and possible (albeit unlikely) direct effects of diltiazem-treated patients compared to three of 30 patients AV nodal ablation on the atria. Since any such collateral on digoxin (P5NS). Recurrence rates at 1 month were also effects would have applied equally to placebo, mibefradil similar in diltiazem (56%) and digoxin (78%) treated and diltiazem groups, we don't believe they affected our patients. The present findings confirm our previous work results. [20] , showing that it is possible to prevent pharmacologically the electrophysiological consequences of atrial tachycardia-related remodeling. Mibefradil has been removedconsistent effects seen.
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